Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant

Saved in:

Bibliographic Details
Published in	British journal of haematology Vol. 196; no. 5; pp. e38 - e40
Main Authors	Le Bourgeois, Amandine, Coste‐Burel, Marianne, Guillaume, Thierry, Peterlin, Pierre, Garnier, Alice, Imbert, Berthe‐Marie, Drumel, Thomas, Mahé, Beatrice, Dubruille, Viviane, Blin, Nicolas, Lok, Anne, Touzeau, Cyrille, Gastinne, Thomas, Tessoulin, Benoît, Jullien, Maxime, Vantyghem, Sophie, Moreau, Philippe, Le Gouill, Steven, Béné, Marie C., Chevallier, Patrice
Format	Journal Article
Language	English
Published	England Blackwell Publishing Ltd 01.03.2022 Wiley John Wiley and Sons Inc
Subjects	Adult Aged allogeneic haematopoietic stem cell transplantation Allografts Antibodies, Viral - immunology Antibody Formation BNT162 Vaccine - administration & dosage BNT162 Vaccine - therapeutic use BNT162b2 Cancer coronavirus disease 2019 (COVID‐19) Correspondence Correspondence‐COVID‐19‐online only COVID-19 - immunology COVID-19 - prevention & control Female Hematology Humans Life Sciences Male Middle Aged mRNA Organ Transplantation Retrospective Studies SARS-CoV-2 - immunology Severe acute respiratory syndrome coronavirus 2 severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) mRNA Stem Cell Transplantation third dose Transplantation, Homologous vaccine Young Adult vaccine third dose BNT162b2 allogeneic haematopoietic stem cell transplantation coronavirus disease 2019 (COVID-19) severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA
Online Access	Get full text
ISSN	0007-1048 1365-2141 1365-2141
DOI	10.1111/bjh.17911

Cover

More Information
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Correspondence-1 PMCID: PMC8653164
ISSN:	0007-1048 1365-2141 1365-2141
DOI:	10.1111/bjh.17911